Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐ Trans Retinoic Acid or Valproic Acid to Decitabine
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14304 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Helena Bresser und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Decitabine, Leukemia, Myeloid, Acute, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In a randomized phase II trial (AMLSG 14‐09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse‐risk genetics, without adding toxicity. We performed a post hoc analysis to determine the predictive impact of TP53 status. Despite a nominally higher ORR, the clinically meaningful survival benefit when adding ATRA to DEC was diminished, but not completely negated, in TP53 ‐mutated patients. Indeed, 2 out of 14 TP53 ‐mutated patients (14%) randomized to a DEC + ATRA‐containing regimen lived for > 36 months. Further studies of ATRA combined with hypomethylating agents appear warranted in non‐M3 AML patients ineligible for HMA/venetoclax therapy. Trial Registration: ClinicalTrials.gov identifier: NCT00867672
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany.
- Clinical Trials Unit, University Medical Center Freiburg, Freiburg, Germany.
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, University Hospital Aachen, Aachen, Germany.
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Department of Medicine III, Technical University Munich School of Medicine, Klinikum Rechts der Isar, Munich, Germany.
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Munich, Munich, Germany.
ORCID-Profile: Helena Bresser
Zitieren
APA
Bresser, H., Schmoor, C., Grishina, O., Pfeifer, D., Thomas, J., Rehman, U. U., Crysandt, M., Jost, E., Thol, F., Heuser, M., Götze, K. S., Schlenk, R. F., Salih, H. R., Schittenhelm, M. M., Heil, G., Schwaenen, C., Müller-Tidow, C., Brugger, W., Kündgen, A., …, & Lübbert, M. (2025). Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐ Trans Retinoic Acid or Valproic Acid to Decitabine. European Journal of Haematology. https://doi.org/10.1111/ejh.14304
Vancouver
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, et al. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐ Trans Retinoic Acid or Valproic Acid to Decitabine. European Journal of Haematology. 2025. doi:10.1111/ejh.14304
BibTeX
@article{Bresser2025,
author = {Bresser, Helena and Schmoor, Claudia and Grishina, Olga and Pfeifer, Dietmar and Thomas, Johanna and Rehman, Usama-Ur and Crysandt, Martina and Jost, Edgar and Thol, Felicitas and Heuser, Michael and Götze, Katharina S and Schlenk, Richard F and Salih, Helmut R and Schittenhelm, Marcus M and Heil, Gerhard and Schwaenen, Carsten and Müller-Tidow, Carsten and Brugger, Wolfram and Kündgen, Andrea and de Wit, Maike and Giagounidis, Aristoteles and Scholl, Sebastian and Neubauer, Andreas and Krauter, Jürgen and Bug, Gesine and May, Annette M and Wäsch, Ralph and Duyster, Justus and Döhner, Konstanze and Ganser, Arnold and Döhner, Hartmut and Hackanson, Björn and Becker, Heiko and Lübbert, Michael},
title = {Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐ Trans Retinoic Acid or Valproic Acid to Decitabine},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14304}
}
EUVIMED